OTC-Ornithine-ZBTB7A Axis Links Liver Dysfunction to CNS Toxicity

Study Background and Research Question

Realgar, a mineral-based traditional Chinese medicine containing arsenic, has been used for centuries in various formulations. Despite its therapeutic applications, chronic or excessive realgar intake can cause adverse effects, particularly central nervous system (CNS) toxicity. Previous clinical and experimental observations have highlighted neurotoxic manifestations—such as cognitive impairment and behavioral disturbances—following prolonged realgar exposure. However, the molecular mechanisms connecting hepatic metabolism, particularly the urea cycle, to arsenic-mediated neurotoxicity have remained insufficiently characterized.

This recent study (Ye et al., 2025) addresses a critical gap: How does realgar-induced hepatic dysfunction, particularly through ornithine transcarbamylase (OTC) inhibition, influence neurotoxic processes in the brain, and what role does L-ornithine play in the propagation of CNS damage?

Key Innovation from the Reference Study

The central innovation of this research lies in elucidating a mechanistic axis spanning hepatic and neural systems. Specifically, the authors demonstrate that realgar-derived arsenic inhibits hepatic OTC, disrupting the urea cycle and resulting in systemic accumulation of L-ornithine ((S)-2,5-diaminopentanoic acid). Elevated ornithine interacts directly with the transcription factor ZBTB7A in astrocytes, triggering repression of glycolytic genes and impairing astrocyte energy metabolism. This mechanistic insight links a canonical liver metabolic pathway—the ammonia detoxification pathway—to astrocyte dysfunction and CNS toxicity, defining a liver–brain axis that integrates metabolic and neurological sequelae of arsenic exposure.

Methods and Experimental Design Insights

The authors employed a multi-layered experimental approach, combining in vivo and in vitro models:

• Animal Models: Mice with conditional knockdown of Zbtb7a in astrocytes (Zbtb7a^{GfABC1D KD}), liver-targeted OTC overexpression (Otc^{TBG OE}), and pharmacological interventions (chrysophanol) were exposed to realgar to assess behavioral, metabolic, and histopathological outcomes.
• Cellular Assays: The C8-D1A astrocyte cell line, transfected with siRNA targeting Zbtb7a, was treated with inorganic arsenic (iAs³⁺) and ornithine to model direct cellular effects.
• Omics and Molecular Analyses: Single-cell transcriptomics and metabolomic profiling provided high-resolution mapping of gene expression and metabolic shifts in both hepatic and neural tissues.
• Neurobehavioral Testing: Cognitive and behavioral phenotypes were quantified using established assays for learning, memory, and anxiety-like behaviors.
• Molecular Docking: Computational analysis demonstrated a specific binding affinity between ornithine and ZBTB7A, supporting the biochemical plausibility of their interaction.

This integrative design enabled the authors to causally link hepatic metabolic disruption to CNS pathophysiology, dissecting both systemic and cell-autonomous mechanisms.

Core Findings and Why They Matter

1. Realgar-derived arsenic crosses the blood–brain barrier and accumulates in the frontal lobe, where it triggers ZBTB7A-dependent repression of glycolytic genes (Aldoa, Ldha, Pgam1) in astrocytes. This suppresses lactate production, resulting in energy deficits, astrocyte apoptosis, and oxidative stress. These changes underpin cognitive and behavioral deficits observed in exposed animals (Ye et al., 2025).

2. Hepatic OTC inhibition by arsenic disrupts the urea cycle, leading to elevated L-ornithine levels systemically and within the CNS. Notably, ornithine—a canonical urea cycle intermediate—was found to directly modulate ZBTB7A activity in astrocytes, further repressing glycolytic gene expression and magnifying neurotoxic outcomes. The molecular docking data support a direct biochemical interaction, reinforcing the mechanistic bridge between hepatic metabolic enzyme dysfunction and CNS pathology.

3. Pharmacological intervention with chrysophanol protected both hepatic and CNS function, preserving astrocyte glycolysis and the integrity of the hepatic ornithine cycle. This suggests that targeting either the urea cycle or astrocyte glycolytic regulation could be a rational strategy to mitigate arsenic-induced neurotoxicity.

4. The study provides new experimental validation for the liver–brain metabolic axis in toxicology. Disruption of the ammonia detoxification pathway in the liver—via inhibition of OTC and subsequent hyperornithinemia—translates into CNS dysfunction through a clearly defined molecular cascade.

Comparison with Existing Internal Articles

The mechanistic framework presented here aligns with and extends themes from several recent resources:

• "L-Ornithine (B8919): Core Facts for Metabolic and Neuroto..." summarizes the experimental utility of high-purity L-ornithine in metabolic enzyme assays and CNS toxicity models, emphasizing the need for reproducibility in studies of urea cycle intermediates.
• "L-Ornithine at the Nexus of Metabolism and Neurotoxicity:..." discusses emerging evidence on the role of L-ornithine as a bridge between hepatic metabolism and neural function, referencing the modulation of ZBTB7A-mediated astrocyte glycolysis as a paradigm for translational research.
• "OTC-Ornithine-ZBTB7A Axis in Realgar-Induced CNS Toxicity" provides a focused review of the same mechanistic axis detailed in the current study, highlighting the significance of liver–brain metabolic interplay in arsenic neurotoxicity.

Collectively, these resources reinforce the current reference study’s conclusion that urea cycle disruption and L-ornithine accumulation serve as critical mechanistic links between hepatic and CNS dysfunction. The present work adds robust experimental and molecular detail to this conceptual bridge, offering new entry points for intervention and assay design in amino acid metabolism research.

Limitations and Transferability

While the study employs comprehensive molecular and behavioral analyses, several limitations merit attention:

• Model specificity: The results are based on murine models and cell lines; direct translation to human pathology requires further validation.
• Dose and exposure window: The concentrations of realgar and duration of exposure may not fully replicate chronic human use scenarios.
• Complexity of CNS metabolism: While the OTC-ornithine-ZBTB7A pathway is clearly implicated, other parallel mechanisms in astrocyte and neuronal metabolism could contribute to observed phenotypes and warrant additional investigation.
• Scope of intervention: The study focuses on chrysophanol as a protective agent, but broader screening of potential modulators of the urea cycle intermediate pool or transcriptional regulation in astrocytes may yield further translational insights.

Despite these limitations, the experimental strategies and protocols described are highly transferable to studies of metabolic enzyme assays, urea cycle disorders, and translational models of neuro-metabolic toxicology.

Protocol Parameters

• Realgar administration (mouse model): Dose and route should align with established toxicity studies; in this reference, chronic exposure was used to model cumulative arsenic effects.
• Conditional OTC modulation: Use of liver-targeted gene overexpression or knockdown to dissect enzyme-specific effects on the urea cycle.
• Astrocyte glycolysis assays: Quantify expression of glycolytic genes (Aldoa, Ldha, Pgam1) and lactate output following manipulation of ZBTB7A or exposure to urea cycle intermediates such as L-ornithine.
• Metabolomic analysis: Employ high-resolution LC-MS to measure plasma and brain L-ornithine concentrations and related urea cycle intermediates.
• Behavioral phenotyping: Incorporate maze navigation, memory, and anxiety assays to link metabolic changes to neurobehavioral outcomes.
• Cellular exposure studies: Treat cultured astrocytes with defined concentrations of iAs³⁺ and L-ornithine (use aqueous solutions for optimal solubility, as reported in APExBIO product information), monitoring cell viability and glycolytic gene expression.

Research Support Resources

For investigators designing metabolic enzyme assays or modeling the liver–brain axis in neurotoxicity, high-quality research reagents are critical. L-Ornithine (SKU B8919) from APExBIO, verified by MS and NMR, offers well-characterized purity and aqueous solubility, supporting reproducibility in workflows focused on urea cycle intermediates and ammonia detoxification pathways. Researchers can integrate such reagents into protocols based on the current study, facilitating rigorous investigation of hepatic and neural metabolic crosstalk.